Dr Reddy’s reports Q2 FY27 revenue decline and plans semaglutide relaunch
Dr Reddy’s Laboratories posted fiscal Q2 2027 revenue of ₹8,671 crore, a 1.5% year‑over‑year drop, and an operating profit of $132.2 million, down 71.6% from the prior year. Net income fell to $96.4 million, and diluted EPS slipped to $0.12. The company announced it will relaunch its generic semaglutide product in November 2026, with most supply earmarked for Canada.
Why it matters
The sharp profit decline and lower earnings per share reduce the company’s near‑term cash generation, which may affect dividend expectations (the company’s own release notes the cash‑from‑operations fell 67.4%). The planned semaglutide relaunch is expected to boost future margins, as the company said it will help improve profitability in coming quarters.
Key facts
- 1Revenue was ₹8,671 crore, down 1.5% year‑over‑year. investing.com
- 2Revenue was $903.9 million, down 8.8% year‑over‑year. quiverquant.com
- 3Operating profit was $132.2 million, down 71.6% year‑over‑year. quiverquant.com
- 4Net income was $96.4 million, down 40.4% year‑over‑year. quiverquant.com
- 5EBITDA margin was 20.6% for the quarter. investing.com
- 6The company plans to relaunch semaglutide in November 2026. finance.yahoo.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.